Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the ...

Meridia RE IV SOCIMI SA ( ($FR:MLMIV) ) has issued an update. Meridia RE IV SOCIMI SA has released its consolidated quarterly ...

Following this positive development, the Company will release its fourth quarter 2024 results prior to 8:30AM US Eastern Time on Thursday, February 20, 2025. At 8:30AM US Eastern Time on the same day, ...